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Abstract
Background: Lipopolysaccharide (LPS) preconditioning-induced neuroprotection is known to be related to
suppression of the inflammatory response in the ischemic area. This study seeks to determine if monocyte
chemotactic protein-induced protein 1 (MCPIP1), a recently identified CCCH Zn finger-containing protein, plays a
role in focal brain ischemia and to elucidate the mechanisms of LPS-induced ischemic brain tolerance.
Methods: Transcription and expression of MCPIP1 gene was monitored by qRT-PCR and Western blot. Mouse
microglia was prepared from cortices of C57BL/6 mouse brain and primary human microglia was acquired from
Clonexpress, Inc. Wild type and MCPIP1 knockout mice were treated with LPS (0.2 mg/kg) 24 hours before brain
ischemia induced by transient middle cerebral artery occlusion (MCAO). The infarct was measured by 2,3,5-
triphenyltetrazolium chloride (TTC) staining.
Results: MCPIP1 protein and mRNA levels significantly increased in both mouse and human microglia and mouse
brain undergoing LPS preconditioning. MCPIP1 mRNA level significantly increased in mice ipsilateral brain than that
of contralateral side after MCAO. The mortality of MCPIP1 knockout mice was significantly higher than that of wild-
type after MCAO. MCPIP1 deficiency caused significant increase in the infarct volume compared with wild type
mice undergoing LPS preconditioning. MCPIP1 deficiency caused significant upregulation of proinflammatory
cytokines in mouse brain. Furthermore, MCPIP1 deficiency increased c-Jun N terminal kinase (JNK) activation
substantially. Inhibition of JNK signaling decreased the production of proinflammatory cytokines in MCPIP1 knock
out mice after MCAO.
Conclusions: Our data indicate that absence of MCPIP1 exacerbates ischemic brain damage by upregulation of
proinflammatory cytokines and that MCPIP1 participates in LPS-induced ischemic stroke tolerance.
Keywords: Ischemic stroke, lipopolysaccharide (LPS) preconditioning, monocyte chemotactic protein-induced pro-
tein 1 (MCPIP1), middle cerebral artery occlusion (MCAO), proinflammatory cytokines
Background
Stroke is the second leading cause of death and the
most frequent cause of permanent disability worldwide
[1]. Inflammatory mechanisms that are activated within
hours after brain ischemia represent a key target of cur-
rent translational ischemic stroke research [2]. It has
been reported that the levels of proinflammatory
cytokines and chemokines are increased after focal
ischemia. Chemokines are cytokines that have the ability
to induce chemotaxis on neighboring cells, particularly
those involved in inflammatory actions [3,4]. While
some cytokines may offer protection, many cytokines
and most chemokines have been shown to participate in
the neuronal damage processes [4,5]. Upregulation of
cerebral proinflammatory cytokines, activation of local
microglia, astrocytes and systemic lymphocytes and * Correspondence: jian.liang@ucf.edu
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tially to ischemic brain damage [6].
Published data have shown that lipopolysaccharide
(LPS) preconditioning is a powerful neuroprotective
phenomenon by which a sublethal injurious stimulus
renders the brain resistant to a subsequent damaging
ischemic insult [7-11]. LPS preconditioning-induced
neuroprotection is related to the suppression of the
inflammatory response in the ischemic area of the brain,
but the mechanisms involved in LPS preconditioning
are poorly understood [12,13].
MCPIP1 (also known as ZC3H12A) is a recently iden-
tified protein in human peripheral blood monocytes
treated with monocyte chemotactic protein 1 (MCP-1)
[14]. In our previous studies, MCPIP1 was shown to be
a negative regulator of macrophage activation [15].
Further investigations by our group and others indicated
that MCPIP1 can play a significant anti-inflammatory
role by inhibiting the generation of a set of major proin-
flammatory cytokines [16,17]. MCPIP1 was also found
to be inducibly expressed in monocytes, macrophages,
and endothelial cells with LPS stimulation [13,17-19].
H o w e v e r ,t h er o l eo fM C P I P 1i ni s c h e m i cs t r o k eh a s
not been examined. In this study we examined MCPIP1
gene expression in human and mouse microglia, and in
mouse brain under LPS treatment or preconditioning.
We also examined MCPIP1 gene expression in mouse
brain undergoing MCAO. We studied whether there is
loss of LPS preconditioning-induced ischemic stroke tol-
erance in MCPIP1 knockout mice and whether such
effects involve regulation of expression of proinflamma-
tory cytokines. Furthermore we investigated the effects
of MCPIP1 on JNK signal pathway under brain ischemia
conditions and the effects of JNK inhibitor on the pro-
duction of proinflammatory cytokines in MCPIP1
knockout mice after brain ischemia. Our data indicate
that MCPIP1 is upregulated under LPS preconditioning
or after brain ischemia stress and MCPIP1 participates
in LPS preconditioning-induced ischemic stroke toler-
ance by modulating gene expression of proinflammatory
cytokines.
Methods
Animals and LPS preconditioning
MCPIP1 knockout mice were established as previously
described [16]. Briefly, Mcpip1
-/- mice was generated by
homologous recombination in embryonic stem cells
from C57/BL6 background mice. Exons 3, 4, 5 and most
part of 6 of mouse Mcpip1 were targeted with a LacZ-
neomycin cassette in embryonic stem cells established
from C57/BL6 mice and established Mcpip1
-/- mice in
pure C57/BL6 background. The deletion of MCPIP1
p r o t e i ni nM c p i p
-/- mice was confirmed by Immuno-
blotting. Six to eight-week-old mice were used. All
experimental procedures were approved by the Institu-
tional Animal Care and Use Committee of University of
Central Florida. We performed all the experiments by
using littermate mice. For in vivo study mice were given
an intraperitoneal injection of saline or LPS (Sigma,
USA) 0.2 mg/kg in saline 24 hours before transient mid-
dle cerebral artery occlusion (MCAO) [12].
Cell cultures
Human microglia was acquired from Clonexpress, Inc.
(Gaithersburg, MD, USA) and cultured in 50:50 DMEM:
F-12 supplemented with 10% FBS and 10 ng/ml of M-
CSF, grown at 37°C in a humidified environment (5%
CO2; 95% air). Mouse microglia cultures were generated
by the procedures described by Watson and colleagues
[20]. In brief, mouse microglia was prepared from cor-
tices of C57BL/6 mouse brain. Brain tissue was placed
in 2 ml Dulbecco’s modified Eagle’s medium (DMEM;
Invitrogen, USA) supplemented with 10% fetal bovine
serum (Gibco, USA), penicillin (100 U/ml; Gibco, USA)
and streptomycin (100 U/ml; Gibco, USA). Samples
were triturated, passed through a sterile nylon mesh fil-
ter; centrifuged (1500 rpm, 5 min, 20-22°C) and the pel-
lets were resuspended in DMEM. Cells were grown in
T25 flasks in DMEM medium supplemented with 10%
FBS. After 12 days the flasks were shaken for 2 hours at
110 rpm at room temperature and tapped several times
to remove the non-adherent microglia. The supernatant
was centrifuged at 1500 rpm for 5 min and the pellet
was resuspended in normal DMEM medium mentioned
above for experiments. LPS (Catalog #, L4516, Sigma,
USA) or PBS was added to medium (0.1 μg/ml) for cell
stimulus experiments.
Mouse focal brain ischemia reperfusion model
For focal brain ischemia, mouse reversible middle cere-
bral artery occlusion (MCAO) was produced by filament
occlusion of the right MCA following a modification of
the method reported by Clark and colleagues [21]. In
brief, mice were anesthetized with isoflurane (induction
with 3%; maintenance with 1.2%) in oxygen-enriched air
by facemask, and rectal temperature was controlled at
37 ± 0.5°C throughout the experiment with heating
lamps. Unilateral MCAO was performed by inserting a
7-0 nylon monofilament into the internal carotid artery
via an external carotid artery stump and then position-
ing the filament tip for occlusion at a distance of 8-9
mm beyond the internal carotid/pterygopalatine artery
bifurcation. MCA was occluded for 90 minutes followed
by reperfusion.
Brain infarction measurement
The brains were stained with 2,3,5-triphenyltetrazolium
chloride (TTC) (Sigma, USA) to determine infarct
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reperfusion, mice were anesthetized with 4% isoflurane
and brains were removed and sectioned coronally at a
thickness of 2 mm and incubated in 2% TTC at 37°C
for 20 minutes. Brain slices were then fixed in 4% paraf-
ormaldehyde at 4°C overnight and scanned into a com-
puter, and quantified using the Image J software. Infarct
volume was expressed as a percentage of the contralat-
eral hemisphere. There were 10 mice in each group.
Brain edema measurement
T h em i c ew e r ea n e s t h e t i z e dw i t h4 %i s o f l u r a n ea n d
brains were removed at different time points, i.e., 12, 24,
and 48 h after MCAO. The brains were weighed to
obtain the wet weight and were then dried at 105°C for
24 h before measuring dry weight. Brain moisture con-
tent (%) was calculated as follows, 100 × (wet weight-
dry weight)/wet weight. There were ten mice in each
group.
Quantitative real-time PCR
Quantitative Real Time-PCR was performed as pre-
viously described [15]. Briefly, Total RNA was isolated
using RNA STAT-60 reagent (TEL-TEST, INC. USA),
after removing the genomic DNA using DNase I
(Ambion, USA), 2.0 ug of total RNA from microglia or
mouse brain tissue was reverse-transcribed to cDNA
using a commercially available kit (Applied Biosystems,
USA). Quantitative real-time PCR was performed with
iCycler Thermal Cycler (Bio-Rad, USA) using 2 × SYBR
Green master mixes (Bio-Rad, USA). Forty cycles were
conducted as follows: 95°C for 30 s, 60°C for 30 s, pro-
ceeded by 10 min at 95°C for polymerase activation.
Quantification was performed by the delta cycle time
method, with mouse b-actin used for normalization.
Human MCPIP1 gene specific primers (IDT, USA) were
F: 5’-GCCGGCGGCCTTA; R: 5’-GCACTGCTCACTCT
CTGTTAGCA. The mouse specific primers (IDT, USA)
are as follows, MCPIP1: F: 5’-CCCCCTGACGACCCTT-
TAG; R: 5’- GGCAGTGGTTTCTTACGAAGGA,
TNFa:F :5 ’- CTGAGGTCAATCTGCCCAAGTAC; R:
5’-CTTCACAGAGCAATGACTCCAAAG, IL-1b:F :5 ’-
GCCCATCCTCTGTGACTCAT; R: 5’- AGGCCA-
CAGGTATTTTGTCG, IL-6: F: 5’- TCGTGGAAATGA-
GAAAAGAGTTG; R: 5’- AGTGCATCATCGTTG
TTCATACA, MCP-1: F: 5’- CCATCTCTGACCTGC
TCTTCCT; R: -AGACCCACTCATTTGCAGCAT, b-
a c t i n :F :5 ’- AAATCGTGCGTGACATCAAAGA; R: 5’-
GGCCATCTCCTGCTCGAA.
Western blot
Western blot was performed as previously described
[15]. Proteins from microglia or mouse brain tissue
were extracted and concentrations were determined by
the Bradford method (Bio-Rad, USA) with bovine serum
albumin as the standard. Proteins (50 ug) were sepa-
rated by SDS-PAGE and transferred onto nitrocellulose
membranes in transfer buffer containing 0.1% SDS. The
membranes were blocked with 5% nonfat dry milk in
0.05% Tween 20 in Tris-buffered saline (TTBS) for 2 h
and incubated with the primary antibodies against
MCPIP1 (Catalog #, sc136750, Santa Cruz, USA), phos-
phor-SAPK/JNK (Catalog #, 9251, Cell Signaling, USA),
SAPK/JNK (Catalog #, 9252, Cell Signaling, USA), phos-
phor-c-jun (Catalog #, 2361, Cell Signaling, USA), c-jun
(Catalog #, 2315, Cell Signaling, USA) at a 1:1000 dilu-
tion in the blocking buffer, 4°C, gently shaking, over-
night. After being washed with TTBS three times for 10
min each, the membranes were incubated with a 1:2,000
dilution of secondary antibody (Santa Cruz, USA) in
TTBS for 1 h. Following three 10-min washes with
TTBS, membranes were incubated with SuperSignal
West Pico Chemiluminescent Substrate (Pierce, USA)
and exposed to x-ray film. The intensity of bands was
quantified by AlphaImage 2200 (AlphaInnotech, USA).
The ratios between interested protein bands and the
loading control (b-actin, total JNK or c-jun) were calcu-
lated and the data are expressed as the normalized folds
with respect to sham.
Drug administration
JNK specific inhibitor SP600125 (Sigma, USA) was dis-
solved in PPCES vehicle (30% polyethylene glycol-400/
20% polypropylene glycol/15% cremophor EL/5% etha-
n o l / 3 0 %s a l i n e )a sr e p o r t e d[ 2 3 ]a n dw a st r e a t e db y
mice tail-vein injection 1 h before ischemia at a dose of
15 mg/kg.
Statistical analysis
The data are presented as mean ± SD. Multiple compar-
isons were evaluated by one-way ANOVA followed by
the Tukey or Dunnett test. Two-group comparisons
were analyzed by the 2-tailed Student t test. For all ana-
lyses, a value of P < 0.05 was considered significant.
Results
MCPIP1 induction in mouse and human microglia by LPS
treatment
In ischemic stroke, microglia is activated after brain
ischemia and release inflammatory cytokines that
exacerbate brain injury. We examined whether LPS
induces MCPIP1 in mouse microglia. The MCPIP1
mRNA level in mouse microglia was significantly
induced by LPS (0.1 μg/ml) treatment compared to PBS
controls; significant increase of MCPIP1 in transcript
level was detected at 3 h and reached 11.12 ± 1.63 fold
at 24 h after LPS treatment (P < 0.001; Figure 1A). Con-
sistently, the MCPIP1 protein levels in mouse microglia
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than in the controls, 5.93 ± 0.72 fold on 24 h after LPS
treatment (P < 0.05; Figure 1B). The MCPIP1 mRNA
level in human microglia was significantly higher in the
LPS (0.1 μg/ml) group than that in the controls at 24 h
after LPS treatment (9.35 ± 1.76 folds, P < 0.001; Figure
2A). The MCPIP1 protein level in human microglia was
also significantly higher in LPS (0.1 μg/ml) group than
that of control (5.65 ± 1.23 folds, P < 0.01; Figure 2B).
MCPIP1 induction in mouse brain cortex after LPS
preconditioning
To determine whether MCPIP1 expression is induced by
LPS preconditioning in vivo, mice were treated
Figure 1 MCPIP1 mRNA and protein levels are elevated in mouse microglia and brain upon treatment with LPS.( A)M C P I P 1m R N A
expression in mouse microglia treated with LPS (0.1 μg/ml) as measured by qRT-PCR. Values represent mean ± SD, # p < 0.01, § p < 0.001
versus PBS control. (B) MCPIP1 protein levels in mouse microglia treated with LPS (0.1 μg/ml) as measured by Western blot. Results are
representative of three independent experiments. *p < 0.05 versus PBS control. (C) MCPIP1 mRNA expression in mouse brain with LPS-
preconditioning (0.2 mg/kg) as measured by qRT-PCR. Values represent mean ± SD, # p < 0.01, § p < 0.001 versus saline control. (D) MCPIP1
protein levels in mouse brain with LPS-preconditioning (0.2 mg/kg) as measured by Western blot. Results are representative of three
independent experiments. *p < 0.05 versus saline control.
Figure 2 MCPIP1 mRNA and protein increase in human microglia treated with LPS.( A) MCPIP1 mRNA expression in human microglia
treated with LPS (0.1 μg/ml) as measured by qRT-PCR. Values represent mean ± SD, § p < 0.001 versus PBS control. (B) MCPIP1 protein levels in
human microglia treated with LPS (0.1 μg/ml) as measured by Western blot. Results are representative of three independent experiments. # p <
0.01 versus PBS control.
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mice with only saline as reported [12]. MCPIP1 mRNA
levels significantly increased in the brain cortex as a
result of LPS treatment. After 3 hr of LPS treatment the
transcript levels showed substantial increase (3.81 ± 0.53
folds) and the maximal level was reached 24 hr (8.62 ±
1.51 folds) after LPS administration with subsequent
decrease but remaining at 3.27 ± 0.59 folds level even
after 7 days (Figure 1C). MCPIP1 protein levels signifi-
cantly increased in the 24-hours after LPS treatment
(5.23 ± 0.82 folds) and showed further increase until 7
days (Figure 1D). These results suggest that MCPIP1 is
significantly elevated in the mouse brain by LPS precon-
ditioning treatments.
MCPIP1 induction in mouse brain cortex after MCAO
We determined whether MCPIP1 is induced by brain
ischemia stress. We examined MCPIP1 mRNA level in
mouse brain cortex after MCAO. The MCPIP1 mRNA
level in the ipsilateral side of mouse brain was significantly
induced after MCAO compared to the contralateral side;
significant increase of MCPIP1 in transcript level was
detected at 3 h and reached 9.85 ± 2.1 fold at 24 h after
MCAO (P < 0.01; Figure 3), suggesting that MCPIP1 may
play an important role after brain ischemia stress.
Loss of LPS-induced tolerance to ischemic stroke by
MCPIP1 deficiency
We examined the effects of low dose (0.2 mg/kg) of LPS
on ischemic brain infarction and the results showed that
the infarct size of LPS-preconditioned mice was signifi-
cantly reduced compared to that of saline control. (41.5
± 10.1% versus 26.3 ± 6.4%, Figure 4A, B). To determine
whether MCPIP1 is involved in LPS preconditioning-
induced tolerance to ischemic brain injury, MCPIP1
knock out or wild type mice were treated with a low
dose of LPS (0.2 mg/kg), and 24 hours later these mice
were subjected with MCAO for 90 min followed by 48
hours reperfusion. The brain infarct size was assessed
with TTC staining 48 hours after MCAO. MCPIP1
knockout mice failed to evoke LPS-induced tolerance
compared with that of wild type (65.6 ± 12.1% versus
26.3 ± 6.4%, Figure 4A, B). There was no significant dif-
ference in brain infarct between LPS-preconditioning
and control in MCPIP1 knockout mice.
Brain edema and mortality associated with ischemia/
reperfusion (I/R) injury are exacerbated by absence of
MCPIP1
To investigate the possible role of MCPIP in ischemic
injury in the brain we subjected MCPIP1 knockout mice
to reversible middle cerebral artery occlusion (MCAO)
for 90 minutes followed by reperfusion for 72 hours.
Edema is one of the earliest pathological changes after
ischemic neuronal damage, which significantly increases
as early as 20 to 45 mins after MCAO [24]. Our results
show that brain edema was enhanced in a time-depen-
dent manner after MCAO in wild type mice (6 h: 81.31
± 0.19%; 24 h: 82.78 ± 0.23%; 48 h: 85.34 ± 0.33%, Fig-
ure 5B) as compared with the sham-treated group (48 h:
Figure 3 MCPIP1 mRNA increases in ipsilateral brain after MCAO. MCPIP1 mRNA expression in mouse brain was determined at 3 h, 6 h and
24 h after MCAO by qRT-PCR. Values represent mean ± SD, * p < 0.05, # p < 0.01 versus contralateral control. n = 5 per group.
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showed a significantly higher increase in brain edema
after MCAO (6 h: 83.52 ± 0.27%; 24 h: 85.73 ± 0.31%;
48 h: 88.69 ± 0.38%, Figure 5B). MCPIP1 knockout mice
showed significantly lower survival than the wild type
and sham-operated MCPIP1 knockout mice (p < 0.05,
Figure 5A).
Increased proinflammatory cytokine expression
We examined the expression of proinflammatory cyto-
kine transcript in the ischemic brain of the wild type
and MCPIP1 knockout mice after MCAO. TNFa, IL-1b,
IL-6 and MCP-1 expression was substantially upregu-
lated after brain ischemia. Different cytokines showed
similar temporal pattern of this upregulation. These
cytokines were more highly induced in MCPIP1 knock-
out mice compared with that of wild type 6 h, 12 h and
24 h after MCAO (Figure 6).
Activation of c-jun N terminal kinase (JNK) signaling
pathway
JNK/c-jun signaling mediates a wide spectrum of cellu-
lar responses, including infection, inflammation, and
apoptosis [25]. To understand the mechanisms
Figure 4 Loss of LPS-induced brain ischemia tolerance in MCPIP1 KO mice. Wild type and MCPIP1 knockout mice were pretreated with LPS
(0.2 mg/kg) 24 hours before MCAO. (A) Infarct images obtained by TTC staining at 48 h after MCAO. The normal tissue was stained deep red
and the infarct was stained milky. (B) Brain infarcts were assessed 48 hours after MCAO and quantified as percentage area of ischemic
hemisphere. Values represent mean ± SD, *p < 0.05, # p < 0.01 versus wild type, n = 8 mice per group.
Figure 5 MCPIP1 knockout mice in higher mortality and exacerbated edema to brain ischemia/reperfusion caused injury. (A) Eight-
week-old MCPIP1 KO and littermate WT mice were subjected to MCAO for 90 minutes followed by 72 hours of reperfusion; sham-operated mice
had the same procedures except no MCA occlusion. Survival was monitored for 72 hours after the MCAO. MCPIP1 knock out I/R mice showed
lower survival than wild type I/R (p < 0.05) and sham-operated MCPIP1 knock out mice (p< 0.05). n = 12 mice per group. (B) Brain water
content as a measure of brain edema of the ischemic hemisphere. MCPIP1 knockout mice had a significant increase in brain edema at 6, 24, and
48 h after MCAO; Values represent mean ± SD,* p < 0.05 versus wild type group. n = 10 per group.
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MCPIP1 knockout mice after brain ischemia, we exam-
ined the activation of JNK/c-jun signaling pathway. The
phosphorylation of JNK and c-jun significantly increased
in mice after brain ischemia/reperfusion and absence of
MCPIP1 caused marked elevation in the levels of both
JNK and c-jun phosphorylation after ischemia/reperfu-
sion compared with that of wild type (Figure 7A, B, C, D).
Knocking out MCPIP1 increases proinflammatory
cytokines via JNK signaling cascade
We determined whether the increased proinflammatory
cytokine production is mediated via JNK and c-jun sig-
naling pathway. We performed specific JNK inhibition
experiments in vivo with JNK inhibitor SP600125 in
MCPIP1 knock out mice after MCAO. MCPIP1 knock
out mice received the JNK inhibitor SP600125 (15 mg/
kg) before 60 min of transient focal ischemia. SP600125
treatment caused a significant decrease in the levels of
both JNK and c-jun phosphorylation (Figure 8A, B, C,
D) and the expression of proinflammatory cytokines
measured at 12 h and 24 h after MCAO compared with
vehicle group (Figure 8E). These results support the
hypothesis that activation of JNK signaling may be an
integral component of the mechanism underlying the
excessive generation of proinflammatory cytokines after
ischemic brain injury.
Discussion
It is becoming increasingly clear that inflammation and
innate immune response play an important role in the
brain injury after ischemic stroke [26,27]. Inflammatory
mechanisms that are activated within hours after brain
ischemia represent a key target for stroke intervention.
Although it has been known that LPS preconditioning
can induce significant tolerance to ischemic brain injury
and inhibit inflammatory responses such as activation of
microglia, brain neutrophil infiltration and proinflamma-
tory cytokine generation, the molecular mechanisms that
contribute to brain ischemia tolerance by LPS precondi-
tioning are not well-understood. The present study is
the first to examine the role of MCPIP1 in acute
Figure 6 Proinflammatory cytokine expression in the ischemic brain. MCPIP1deficiency significantly elevated the expression of
proinflammatory cytokines TNFa, IL-1b, IL-6 and MCP-1, as measured by q-RT-PCR in the ischemic brain after MCAO. Values represent mean ±
SD, # p < 0.01 and § p < 0.001 versus wild type, n = 6 mice per group.
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icantly induced in human and mouse microglia and
mouse brain with LPS stimulus or preconditioning and
that MCPIP1 gene expression significantly increased in
mouse brain after MCAO. These findings are consistent
w i t ht h es i g n i f i c a n c eo fi n f lammatory processes contri-
buting to the brain damage in ischemic stroke [26] and
the anti-inflammatory properties of MCPIP1 [16,17].
Similarly we also found the upregulation of MCPIP1 in
cultured mice astrocytes following LPS stimulation (data
not shown) and activated astrocytes also play an impor-
tant role in neuroinflammation [28]. Thus, we conclude
that MCPIP1 is involved in LPS preconditioning-
induced ischemic stroke tolerance by its anti-inflamma-
tory activities and MCPIP1 may play an important role
against ischemic brain injury. Consistent with other
reports [7,12] we found that a small dose of LPS given
systemically confers protection against ischemia in
mouse brain with respect to infarct volume. More inter-
estingly, we found that there was loss of LPS-induced
ischemic stroke tolerance by MCPIP1 deficiency. There
was much larger ischemic brain infarct area in MCPIP1
deficient mice compared to the wild type. Higher mor-
tality in MCPIP1 knockout mice subjected to focal brain
ischemia/reperfusion injury compared with wild type
indicated that MCPIP1 deficient mice is more sensitive
to ischemic brain injury than wild type. This result was
not due to the possible general physiological weakness
of MCPIP1 knockout mice to resist stress of surgery as
mortality of sham group of MCPIP1 knockout mice was
much less than the animals subjected to ischemic injury.
Clinical data showed that the principal cause of stroke
death in patients with malignant middle cerebral artery
infarction was focal brain edema [29]. Experimental
models of cerebral infarction show an increase in water
content beginning within hours and peaking at 48 hours
[30]. Progressive postischemic edema would result in
increased intracranial pressure with compression of the
brain stem, occlusive hydrocephalus and secondary
ischemic damage finally followed by clinical deteriora-
tion, coma, and death within 2 to 5 days after stroke
[31,32]. In this study, our data showed that absence of
MCPIP1 significantly increased the infarct volume and
brain edema compared to wild type after ischemia/
reperfusion injury. Thus, severe brain edema may be the
major cause of higher mortality in MCPIP1 knockout
mice subjected to ischemic stroke.
Inflammatory response after stroke significantly con-
tributes to ischemic brain damage, which can be sub-
divided into the cellular response and the cytokine
response [6]. Neutrophils accumulate in the brain as
early as 30 min after permanent middle cerebral artery
Figure 7 Activation of c-Jun N terminal kinase (JNK) signaling pathway. Proteins extracted from the ischemic hemisphere of wild type and
MCPIP1 knockout mice undergoing ischemia 30 min followed by 30 and 90 min reperfusion separately. The samples were subjected to Western
blot analysis with antibodies as indicated. (A) A representative western blot shows protein levels of JNK phosphorylation. (B) Densitometric
analysis was used to quantify p-JNK protein levels versus total JNK in 3 independent western blots and the data are expressed as the normalized
folds with respect to sham. Values represent mean ± SD, *p < 0.05 versus sham-treated control. (C) A representative western blot shows protein
levels of c-jun phosphorylation. (D) Densitometric analysis was used to quantify p-c-cun protein levels versus total c-jun in 3 independent
western blots and the data are expressed as the normalized folds with respect to sham. Values represent mean ± SD, *p < 0.05 versus sham-
treated control.
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adhesion molecules such as vascular cell adhesion mole-
cule (VCAM)-1, intercellular adhesion molecule
(ICAM)-1, and selectin, which contribute to the recruit-
ment of inflammatory cells to endothelial blood vessel
wall [33,34]. When adhered to cerebral blood vessel
walls, neutrophils transmigrate into the cerebral par-
enchyma, which can cause tissue damage by releasing
reactive oxygen species and proteolytic enzymes.
MCPIP1 expression is induced in human blood
endothelial cells and overexpression of MCPIP1 sup-
presses cytokine-induced expression of VCAM-1, as well
as monocyte adhesion to human endothelial cells [19].
Such properties of MCPIP1 helps to explain the present
results that absence of MCPIP1 exacerbates ischemia
induced brain injury.
Proinflammatory cytokines and chemokines contribute
to stroke-related brain injury [6,35]. During ischemia,
cytokines, such as TNF-a,I L - 1 b,I L - 6 ,a n dc h e m o k i n e s
such as CINC and MCP-1 are produced by a variety of
activated cell types, including endothelial cells, micro-
glia, astrocytes and neurons [36]. The deleterious effects
of these cytokines include fever, arachidonic acid release,
enhancement of NMDA mediated excitotoxicity, and sti-
mulation of nitric oxide synthesis. TNFa and IL-1 have
been shown to cause up-regulation of E-selectin, ICAM-
1, ICAM-2, and VCAM-1 on cerebral endothelial cells
and the induction of such adhesion molecules may
explain the elevation of TNFa and IL-1 levels after
ischemia increases neutrophil infiltration [37]. Addition-
ally TNFa can stimulate acute-phase protein produc-
tion, including plasminogen, disrupt the blood-brain
barrier and stimulate the induction of other inflamma-
tory mediators. LPS preconditioning can induce signifi-
cant tolerance to ischemic brain injury and inhibit
inflammatory responses such as activation of microglia,
Figure 8 JNK signaling plays a critical role in proinflammatory cytokines production. MCPIP1 knockout mice were treated with SP600125
(15 mg/kg, iv) 60 min prior to MCAO and proteins extracted from the ischemic hemisphere of MCPIP1 knockout mice undergoing ischemia 30
min followed by 30 and 90 min reperfusion separately. (A) A representative western blot shows protein levels of JNK phosphorylation. (B)
Densitometric analysis was used to quantify p-JNK protein levels versus total JNK in 3 independent western blots and the data are expressed as
the normalized folds with respect to sham. Values represent mean ± SD, *p < 0.05 versus sham-treated control. (C) A representative western blot
shows protein levels of c-jun phosphorylation. (D) Densitometric analysis was used to quantify p-c-cun protein levels versus total JNK as the
loading control in 3 independent western blots and the data are expressed as the normalized folds with respect to sham. Values represent
mean ± SD, *p < 0.05 versus sham-treated control. (E) The expression of proinflammatory cytokines was determined at 12 h and 24 h after
MCAO and inhibition of JNK activation significantly reduced mRNA levels of TNFa and IL-1b in the ischemic hemisphere of MCPIP1 knockout
mice undergoing MCAO. Values represent mean ± SD,* p < 0.05 versus sham group. n = 5 per group.
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Page 9 of 11brain neutrophil infiltration and proinflammatory cyto-
kine generation. Some studies attributed LPS precondi-
tioning to reprograming of cellular response to
ischemia via genomic changes that render the brain
refractory to ischemic injury [11,38]. However, the
molecular mechanisms that mediate the beneficial
effects in LPS-induced ischemic tolerance remains
poorly understood. In this study we observed that
knocking out MCPIP1 increased the brain damage
after ischemic stroke and significantly enhanced the
expression of proinflammatory cytokines in the brain,
which may account for the severe brain damage result-
ing from ischemia in MCPIP1 deficient mice. It has
been established that endotoxin-preconditioning by
LPS, TNFa and IL-1b can induce ischemic tolerance.
Less well studied is what mediates such beneficial tol-
erance in preconditioning process i.e. the necessary
intermediate links for completion of preconditioning
tolerance. If this link is lost, the chain from cytokines
to tolerance would be broken; in other words, even if
cytokines still exist the tolerance would be not induced
or would be inhibited. We hypothesized that MCPIP1
is such an inducible factor or link which mediates, at
least in part, the translation from cytokine stimulation
to tolerance. When MCPIP1 is deficient, tolerance is
reduced even in the presence of more cytokines, as the
key mediator is missing. Our results suggest that
MCPIP1 is such a mediating factor and MCPIP1-defi-
ciency results in the loss of LPS-induced ischemia tol-
erance in the brain and higher level of
proinflammatory cytokines in ischemic brain. How
does MCPIP1 regulate these inflammatory cytokine
responses remains to be fully elucidated. It has been
reported that MCPIP1 might be functioning as an
RNase to promote the degradation of some inflamma-
tory mRNA such as IL-6 and IL-1b [17]. We have
found that MCPIP1 can also act as a deubiquitinase to
negatively regulate JNK and NF-B signaling by target-
ing TNF receptor-associated factors (TRAFs) [16,39],
which suggests that MCPIP1 may control inflammatory
response by multiple mechanisms. Activation of JNK
signaling pathways leads to c-Jun mediated inflamma-
tory cytokine production [24,40,41]. In this study we
found that knocking out MCPIP1 significantly
enhanced the activation of JNK kinase and phosphory-
lation of c-jun in mouse brain after ischemic/reperfu-
sion injury and that administration of the JNK
inhibitor SP600125 reduced hyperphosphorylation of
JNK and c-Jun signaling after cerebral ischemia and
significantly decreased the production of proinflamma-
tory cytokines such as TNFa and IL-1b. Our study
suggests that increased activation of JNK signaling
pathway in MCPIP1 knockout mice leads to increased
proinflammatory cytokine production.
Conclusions
Based on the data, we concluded that MCPIP1 partici-
pates in LPS preconditioning-induced ischemic stroke
tolerance. Knocking out MCPIP1 gene exacerbates brain
damage after cerebral ischemia/reperfusion by upregula-
tion of proinflammatory cytokines.
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